Results for "consumer data right"
471-480 of 575 results for 'consumer data right'
Changes to open and transparent sale process requirement for foreign persons acquiring agricultural land
On 25 September 2018 the Foreign Investment Review Board released revised guidance on the application of the requirement for an open and transparent sale process for foreign persons acquiring agricultural land Partner Wendy Rae Senior Associate Julian Barendse and Lawyer Bianca Sacco examine these ...
Regulatory scrutiny of private capital increases
Private capital is becoming a growing focus of regulators, both in Australia and internationally, given the ever-increasing flow of capital to the sector in recent years. ...
The pitfalls of pre-emptive rights
In this Insight, we consider an alternative approach that may better balance the rights of selling and non-selling investors where a pre-emptive right remains appropriate. ...
New ASIC guidance on how superannuation and managed funds can avoid 'greenwashing'
Greenwashing in the promotion of managed investment and superannuation funds is one of ASIC's current corporate governance priorities as it continues to 'monitor the market … looking for misleading claims about ESG and sustainability'. ...
Dollars and sense: the evolution of executive remuneration practices
The need for robust executive remuneration frameworks is becoming increasingly important as companies tackle the challenges arising out of the COVID-19 pandemic, a heightened regulatory environment and the need to strike the right balance with executives to drive and reward conduct and performance t ...
The ASX Listing Rules up for review but still fit for purpose: the case for retaining the existing policy settings on reverse takeovers
Merger transactions without a vote of the shareholders of each merger party are back in the headlines as a second deal sparks fresh tension and mounting calls from the Australian investment community ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
World first: Australia says ‘yes’ to AI inventors
The decision in Thaler v Commissioner of Patents [2021] FCA 879 is the first judicial determination in the world in favour of AI systems being named as inventors of a patent. The availability of patent protection for AI-generated inventions is a vexed and controversial issue. ...
Recent developments in foreign investment (FIRB) regulation
The Federal Government's recent changes to foreign investment policies released on 14 March 2025 introduce significant modifications. In this Insight, we: examine the Government's latest foreign inve ...
Interlocutory injunction refused based on 'doubtful' patent term extension
In the fight against patent infringement, challenging the validity of patent term extensions (PTEs) is increasingly becoming the weapon of choice for generic pharmaceutical companies. Since around the mid-2000s, patentees in pharmaceutical patent cases have typically been successful in bids for interlocutory injunctions, aiming to prevent the launch of generic products in Australia. The recent Biogen decision by the Federal Court is the latest in a trend of refusing interlocutory injunctions, and a clear indication the tide is turning. ...